TenderlineUK
Procurement Intelligence
Official OCDS
Find a Tender
complete
Official procurement procedure

NHS Genomic Medicine Service - Most Suitable Provider Process

Health services
North East (UKC)
North West (UKD)
West Midlands (UKG)
East of England (UKH)
Published value
Not published
Submission deadline Not published
Lots published7
Procurement Executive Summary
AI & Search Synopsis
Generated from official OCDS record
Tenderline Synopsis: NHS England: "NHS Genomic Medicine Service - Most Suitable Provider Process". Published status: complete. Published value: Value not published. 7 published lots. Submission deadline not published. See the official notice for participation instructions.
Contracting AuthorityNHS EnglandScope & CategoriesNot publishedSubmission Window
complete
No deadline published
Submission GatewayDirect notice routeLegal Basis & RegimeStandard procurementEstimated Value (exc. VAT)Not published
Bidder Intelligence · Authority Profile: NHS England
Market Analytics
View Authority Profile →
Derived from OCDS awards & bid statistics
Published history for NHS England. These figures describe retained records, not a forecast of bids or a measure of buyer bias.
Average Price Reduction
Not availableInsufficient comparable data
Requires at least 5 comparable procedures
Competition Density
49.6Bids / Report
38.2% of reports have one bid
Supplier ConcentrationNo estimate
Insufficient attributable awardsNo concentration estimate available
Payment Terms
Check noticePublished terms
Payment obligations depend on the applicable regime and contract. Consult the official documents.
Coverage: 752 active published awards; 747 bid reports (which may be per lot). Supplier values exclude multi-supplier awards, frameworks and DPS, and use GBP only. They are published award values, not payments. Price reduction compares single-lot, single-award, single-supplier GBP procedures with explicitly non-framework/non-DPS status; increases remain in the average. Unpublished data stays unknown. Awarded suppliers are winners, not all bidders.
Procedure terms
Contracting AuthorityNHS England
Procedure methodNot published
Procurement categoryNot published
Statuscomplete
Framework / DPSNot published
CompetitionNot published
Above thresholdNot published
Legal basisNot published
Tender period startsNot published
Clarification deadlineNot published
Electronic submissionNot published
Submission languagesNot published
Published23 Oct 2025, 17:00 BST
Last source update23 Oct 2025, 17:00 BST
Recurring procurementNot published
ClassificationHealth services
Delivery area
North East (UKC)
North West (UKD)
West Midlands (UKG)
East of England (UKH)
OCIDocds-h6vhtk-0565e9
What is being bought
This is a notice of intention to make an award in respect of the NHS Genomic Medicine Service pursuant to the Most Suitable Provider (MSP) Process for the NHS Genomic Medicine Service (NHS GMS). For the avoidance of doubt, this is an intention to award notice. A notice of the confirmation of the award of each contract will be issued once they are signed.<br/><br/>Pursuant to the NHS GMS contracts, provider are to provide the following functions: <br/>• Organisational leadership, governance and partnership arrangements;<br/>• Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);<br/>• Laboratory operating model;<br/>• Clinical function: cancer genomics;<br/>• Clinical function: rare disease;<br/>• Clinical function: population health;<br/>• Promotion of and supporting and leading where relevant science, research and / or innovation;<br/>• Transformation and Service Improvement;<br/>• People – workforce, education and training; and<br/>• Data and digital
What changed
From the official release history
  1. tender value changed
    23 Oct 2025, 17:00 BST
  2. Status changed to complete
    23 Oct 2025, 17:00 BST
  3. Official notice release published
    23 Oct 2025, 17:00 BST
  4. Published value updated to £3,850,000,000
    24 Jul 2025, 17:52 BST
  5. Status changed to planned
    24 Jul 2025, 17:52 BST
  6. Official notice release published
    24 Jul 2025, 17:52 BST
  7. Buyer information updated
    24 Jul 2025, 17:52 BST
Lots and requirements (7)
Published by the contracting authority
  • Lot 1 · #1
    Lot 1 – NHS North-West GMS
    cancelled
    Published valueNot published
    Pursuant to the NHS GMS contracts, providers are to provide the following functions:<br/>* Organisational leadership, governance and partnership arrangements;<br/>* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);<br/>* Laboratory operating model;<br/>* Clinical function: cancer genomics;<br/>* Clinical function: rare disease;<br/>* Clinical function: population health;<br/>* Promotion of and supporting and leading where relevant science, research and / or innovation;<br/>* Transformation and Service Improvement;<br/>* People – workforce, education and training; and<br/>* Data and digital<br/>The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.<br/>The approximate lifetime value of the contract for all Lots is £5,175,000,000.<br/>The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).<br/>Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 2 · #2
    Lot 2 – NHS North-East and Yorkshire GMS
    cancelled
    Published valueNot published
    Pursuant to the NHS GMS contracts, providers are to provide the following functions:<br/>* Organisational leadership, governance and partnership arrangements;<br/>* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);<br/>* Laboratory operating model;<br/>* Clinical function: cancer genomics;<br/>* Clinical function: rare disease;<br/>* Clinical function: population health;<br/>* Promotion of and supporting and leading where relevant science, research and / or innovation;<br/>* Transformation and Service Improvement;<br/>* People – workforce, education and training; and<br/>* Data and digital<br/>The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.<br/>The approximate lifetime value of the contract for all Lots is £5,175,000,000.<br/>The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).<br/>Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 3 · #3
    Lot 3 – NHS Central and South GMS
    cancelled
    Published valueNot published
    Pursuant to the NHS GMS contracts, providers are to provide the following functions:<br/>* Organisational leadership, governance and partnership arrangements;<br/>* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);<br/>* Laboratory operating model;<br/>* Clinical function: cancer genomics;<br/>* Clinical function: rare disease;<br/>* Clinical function: population health;<br/>* Promotion of and supporting and leading where relevant science, research and / or innovation;<br/>* Transformation and Service Improvement;<br/>* People – workforce, education and training; and<br/>* Data and digital<br/>The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.<br/>The approximate lifetime value of the contract for all Lots is £5,175,000,000.<br/>The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).<br/>Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 4 · #4
    Lot 4 – NHS East GMS
    cancelled
    Published valueNot published
    Pursuant to the NHS GMS contracts, providers are to provide the following functions:<br/>* Organisational leadership, governance and partnership arrangements;<br/>* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);<br/>* Laboratory operating model;<br/>* Clinical function: cancer genomics;<br/>* Clinical function: rare disease;<br/>* Clinical function: population health;<br/>* Promotion of and supporting and leading where relevant science, research and / or innovation;<br/>* Transformation and Service Improvement;<br/>* People – workforce, education and training; and<br/>* Data and digital<br/>The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.<br/>The approximate lifetime value of the contract for all Lots is £5,175,000,000.<br/>The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).<br/>Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 5 · #5
    Lot 5 – NHS South-West GMS
    cancelled
    Published valueNot published
    Pursuant to the NHS GMS contracts, providers are to provide the following functions:<br/>* Organisational leadership, governance and partnership arrangements;<br/>* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);<br/>* Laboratory operating model;<br/>* Clinical function: cancer genomics;<br/>* Clinical function: rare disease;<br/>* Clinical function: population health;<br/>* Promotion of and supporting and leading where relevant science, research and / or innovation;<br/>* Transformation and Service Improvement;<br/>* People – workforce, education and training; and<br/>* Data and digital<br/>The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.<br/>The approximate lifetime value of the contract for all Lots is £5,175,000,000.<br/>The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).<br/>Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 6 · #6
    Lot 6 – NHS North Thames GMS
    cancelled
    Published valueNot published
    Pursuant to the NHS GMS contracts, providers are to provide the following functions:<br/>* Organisational leadership, governance and partnership arrangements;<br/>* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);<br/>* Laboratory operating model;<br/>* Clinical function: cancer genomics;<br/>* Clinical function: rare disease;<br/>* Clinical function: population health;<br/>* Promotion of and supporting and leading where relevant science, research and / or innovation;<br/>* Transformation and Service Improvement;<br/>* People – workforce, education and training; and<br/>* Data and digital<br/>The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.<br/>The approximate lifetime value of the contract for all Lots is £5,175,000,000.<br/>The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).<br/>Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 7 · #7
    Lot 7 – NHS South-East GMS
    cancelled
    Published valueNot published
    Pursuant to the NHS GMS contracts, providers are to provide the following functions:<br/>* Organisational leadership, governance and partnership arrangements;<br/>* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);<br/>* Laboratory operating model;<br/>* Clinical function: cancer genomics;<br/>* Clinical function: rare disease;<br/>* Clinical function: population health;<br/>* Promotion of and supporting and leading where relevant science, research and / or innovation;<br/>* Transformation and Service Improvement;<br/>* People – workforce, education and training; and<br/>* Data and digital<br/>The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.<br/>The approximate lifetime value of the contract for all Lots is £5,175,000,000.<br/>The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).<br/>Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
Timeline
  1. Procedure published
    23 Oct 2025, 17:00 BST
  2. Award active
    Not published · Not published
  3. Award active
    Not published · Not published
  4. Award active
    Not published · Not published
  5. Award active
    Not published · Not published
  6. Award active
    Not published · Not published
  7. Award active
    Not published · Not published
  8. Award active
    Not published · Not published
  9. Contract active
    Signed 21 Oct 2025, 00:00 BST · £5,175,000,000
  10. Contract active
    Signed 21 Oct 2025, 00:00 BST · £5,175,000,000
  11. Contract active
    Signed 21 Oct 2025, 00:00 BST · £5,175,000,000
  12. Contract active
    Signed 21 Oct 2025, 00:00 BST · £5,175,000,000
  13. Contract active
    Signed 21 Oct 2025, 00:00 BST · £5,175,000,000
  14. Contract active
    Signed 21 Oct 2025, 00:00 BST · £5,175,000,000
  15. Contract active
    Signed 21 Oct 2025, 00:00 BST · £5,175,000,000
Commercial outcome and competition
Awards
Manchester University NHS Foundation Trust
Not published · Not published · active
The Newcastle upon Tyne Hospitals NHS Foundation Trust
Not published · Not published · active
Birmingham Women’s and Children’s NHS Foundation Trust
Not published · Not published · active
Cambridge University Hospitals NHS Foundation Trust
Not published · Not published · active
North Bristol NHS Trust
Not published · Not published · active
Great Ormond Street Hospital for Children NHS Foundation Trust
Not published · Not published · active
Guy's and St Thomas' NHS Foundation Trust
Not published · Not published · active
Contracts
Lot 1 - NHS North-West GMS
£5,175,000,000 · signed 21 Oct 2025, 00:00 BST · active
Lot 2 - NHS North-East and Yorkshire GMS
£5,175,000,000 · signed 21 Oct 2025, 00:00 BST · active
Lot 3 NHS Central and South GMS
£5,175,000,000 · signed 21 Oct 2025, 00:00 BST · active
Lot 4 NHS East GMS
£5,175,000,000 · signed 21 Oct 2025, 00:00 BST · active
Lot 5 NHS South-West GMS
£5,175,000,000 · signed 21 Oct 2025, 00:00 BST · active
Lot 6 NHS North Thames GMS
£5,175,000,000 · signed 21 Oct 2025, 00:00 BST · active
Lot 7 NHS South-East GMS
£5,175,000,000 · signed 21 Oct 2025, 00:00 BST · active
Bid statistics
bids: 3 (lot 1)
bids: 3 (lot 2)
bids: 3 (lot 3)
bids: 3 (lot 4)
bids: 3 (lot 5)
bids: 3 (lot 6)
bids: 3 (lot 7)
Buyer and organisations in this procedure

NHS England

Contracting authority GB-FTS-118033
View buyer profile

  • NHS England
    buyer

    7&8 Wellington Place, Leeds, UKE, LS1 4AP
    anna.salt@nhs.net

  • Birmingham Women’s and Children’s NHS Foundation Trust
    supplier

    Birmingham, UKG3

  • Cambridge University Hospitals NHS Foundation Trust
    supplier

    Cambridge, UKH1

  • Great Ormond Street Hospital for Children NHS Foundation Trust
    supplier

    London, UKI3

  • Guy's and St Thomas' NHS Foundation Trust
    supplier

    London, UKI3

  • Manchester University NHS Foundation Trust
    supplier

    Manchester, UKD3

  • NHS Arden and Greater East Midlands Commissioning Support Unit
    reviewBody

    Cardinal Square, 10 Nottingham Road, Derby, DE1 3QT

  • North Bristol NHS Trust
    supplier

    Bristol, UKK1

  • The Newcastle upon Tyne Hospitals NHS Foundation Trust
    supplier

    Newcastle, UKC2
Documents (0)
Official links; attachments are not copied
No data
No linked documents are published
Related procedures (0)
No data
No related procedures published
Planning and rationale
Planning budgetNot published
No-engagement rationaleNot published
Procedure rationaleThis is a Provider Selection Regime (PSR) intention to award notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Procurement Act Regulations 2023 do not apply to this award. The standstill period begins on the day after the publication of this notice. Representations by providers must be made to decision makers by Tuesday 4th November 2025. This contract has not yet formally been awarded; this notice serves as an intention to award under the PSR.